Healthcare
Vor Biopharma Inc.(VOR)
Live Price
Offline$14.36
+1.92% today
1Y Change
+147.59%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- $100.00M
- Revenue Growth
- 0.0%
- EPS Growth
- -107.4%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Vor Biopharma Inc. (VOR) is a Healthcare stock with a market cap of $100.00M and listed on NASDAQ. The stock last traded around $14.36 and up 147.6% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -107.4%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -107.4%, free cash flow -43.8% with operating margin 0.0% and ROIC -84.6%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines VOR price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 13, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -107.4%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -15.4% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 13, 2026 | โ | -5.3% | -2.3% | -11.4% |
2026 Apr 2, 2026 | +4686.0% | -9.9% | -14.3% | -23.3% |
2025 Nov 13, 2025 | -8.8% | +2.7% | -29.6% | +28.3% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VOR
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
VOR Max Drawdown
-87.15%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for VOR and SPY.
Company Overview
Vor Biopharma Inc.
NASDAQ Global Select
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
- Leadership
- Jean-Paul Kress
- IPO Date
- Feb 5, 2021
- Employees
- 159
- Street Address
- 100 Cambridgepark Drive
- Mailing
- Cambridge, MA, 02140
- Region
- Cambridge, MA, US
- Reporting Currency
- USD
- Investor Line
- 617 655 6580
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 0.3
- Price/Sales
- โ
- Price/Book
- โ
Growth
- Revenue
- 0.0%
- EPS
- -107.4%
- Free Cash Flow
- -43.8%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- 72.7%
- ROIC
- -84.6%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 18.20
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.